Compare Davita Inc (DVA) vs iShares China Large-Cap ETF (FXI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares China Large-Cap ETF — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while iShares China Large-Cap ETF trades at $34.27 (market cap $3.86B). The key difference: Davita Inc is far larger — about 2.9× iShares China Large-Cap ETF's market cap, and Davita Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and iShares China Large-Cap ETF for 150 Days on average.
| DVA | FXI | |
|---|---|---|
Market Cap | $11.29B | $3.86B |
Volume | 582,204 | 16,323,837 |
Sector | Health | — |
52-Week High | $240.96 | $41.08 |
52-Week Low | $103.87 | $31.59 |
Typical Hold Time | 114 Days | 150 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
FXI trades at $34.19, up 2.3% today, but technical indicators show a bearish trend with 17 sell signals versus 1 buy. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent U.S.-China diplomatic engagement offers potential for reduced trade tensions, but momentum remains weak with the ETF trading near key support at $33.
FXI presents a value opportunity trading at half the S&P 500's P/E ratio with a 1.98% yield, but requires tolerance for significant geopolitical risk. The ETF's heavy financial sector exposure and China's export-driven economy face protectionism threats, making it suitable only for diversified portfolios with high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →
